Summary

Global Amyotrophic Lateral Sclerosis Market: Overview

The increasing awareness of ALS, advancements in genetic research, and a growing pipeline of therapeutic drugs targeting ALS are driving the market’s growth. ALS is a progressive neurodegenerative disease affecting motor neurons, and with the advancements in science, the treatment landscape is becoming increasingly targeted and effective.

Amyotrophic lateral sclerosis is characterized by the progressive degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, disability, and eventually, death. With significant research efforts aimed at understanding its molecular mechanisms, innovative therapeutic solutions are emerging. As a result, the amyotrophic lateral sclerosis market is on the cusp of a breakthrough in terms of treatment options.

Market Lifecycle Stage

The market for amyotrophic lateral sclerosis treatments is in a rapidly evolving phase, shifting from symptomatic management toward more targeted therapies aimed at modifying the disease progression. While current treatments mainly focus on slowing the progression of amyotrophic lateral sclerosis and providing symptomatic relief, newer interventions are beginning to explore the genetic and molecular mechanisms underlying the disease. Disease-modifying therapies (DMTs), gene therapies, and biologic agents hold the potential to significantly alter the treatment landscape for amyotrophic lateral sclerosis patients.

North America is expected to maintain its dominant position in the global amyotrophic lateral sclerosis market, driven by a well-established healthcare infrastructure, a high rate of diagnosis, and substantial investment in amyotrophic lateral sclerosis research. The U.S. market is projected to grow at a CAGR of XX% during the forecast period, supported by the increasing number of clinical trials, government funding for rare diseases, and a growing amyotrophic lateral sclerosis patient population. Major pharmaceutical companies, research institutions, and healthcare providers are focused on advancing treatment options for amyotrophic lateral sclerosis in the region, which is expected to drive further market expansion.

Demand - Drivers and Limitations

The global amyotrophic lateral sclerosis market is driven by several key factors:

• Rising prevalence of amyotrophic lateral sclerosis cases will drive market demand
• Advances in genetic research, coupled with improved understanding of the molecular mechanisms involved in amyotrophic lateral sclerosis
• An increase in clinical trials and investments will accelerate the development of innovative treatments for amyotrophic lateral sclerosis

Limitations:

• The high cost of amyotrophic lateral sclerosis treatments may limit accessibility and market growth
• Lack of awareness in emerging markets will hinder the adoption of amyotrophic lateral sclerosis treatments

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: This report provides valuable insights for pharmaceutical companies and biotech firms looking to develop new amyotrophic lateral sclerosis treatments, focusing on genetic therapies, precision medicine, and biologics that target amyotrophic lateral sclerosis-specific molecular pathways. It helps identify emerging trends and the potential for breakthrough therapies that can modify disease progression.

Competitive Strategy: Pharmaceutical companies and healthcare providers can use the information in this report to evaluate the current competitive landscape, assess market trends, and develop strategies that ensure long-term success in the global amyotrophic lateral sclerosis Market. Understanding the major players, new entrants, and their strategies will help companies stay ahead of the competition.

Key Market Players and Competition Synopsis

The companies profiled in this report are selected based on expert insights, evaluating company coverage, product portfolio, and market penetration. Leading players in the global amyotrophic lateral sclerosis market include pharmaceutical companies who hold substantial shares of the market.

Some of the prominent names established in this market are:

• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Aquestive Therapeutics, Inc.
• Ionis Pharmaceuticals
• MediciNova
• AB Science
• Brainstorm-Cell Therapeutics
• Italfarmaco S.p.A.

ページTOPに戻る

Table of Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria
1. Global Amyotrophic Lateral Sclerosis Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis of Amyotrophic Lateral Sclerosis
1.2.1 U.S.
1.2.2 EU5
1.3 Market Trends
1.4 Clinical Trials
1.4.1 By Phase
1.5 Regulatory Landscape Analysis
1.5.1 Legal Requirement and Framework in U.S.
1.5.2 Legal Requirement and Framework in E.U.
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Amyotrophic Lateral Sclerosis Market, by Region, $Million, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Amyotrophic Lateral Sclerosis Market (by Country)
2.1.3.1.1 U.S.
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Amyotrophic Lateral Sclerosis Market (by Country)
2.2.3.1.1 Germany
2.2.3.1.2 France
2.2.3.1.3 Italy
2.2.3.1.4 U.K.
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis Market (by Country)
2.3.3.1.1 Japan
3. Global Amyotrophic Lateral Sclerosis Market - Competitive Benchmarking and Company Profiles
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments by Company
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 Mitsubishi Tanabe Pharma Corporation
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Key Personnels
3.2.1.5 Analyst View
3.2.2 Biogen Inc.
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers / End Users
3.2.2.4 Key Personnels
3.2.2.5 Analyst View
3.2.3 Aquestive Therapeutics, Inc.
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers / End Users
3.2.3.4 Key Personnels
3.2.3.5 Analyst View
3.2.4 Ionis Pharmaceuticals
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers / End Users
3.2.4.4 Key Personnels
3.2.4.5 Analyst View
3.2.5 MediciNova
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers / End Users
3.2.5.4 Key Personnels
3.2.5.5 Analyst View
3.2.6 AB Science
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers / End Users
3.2.6.4 Key Personnels
3.2.6.5 Analyst View
3.2.7 Brainstorm-Cell Therapeutics
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers / End Users
3.2.7.4 Key Personnels
3.2.7.5 Analyst View
3.2.8 Italfarmaco S.p.A.
3.2.8.1 Company Overview
3.2.8.2 Product Portfolio
3.2.8.3 Target Customers / End Users
3.2.8.4 Key Personnels
3.2.8.5 Analyst View
4. Research Methodology
List of Figures
Figure: Global Amyotrophic Lateral Sclerosis Market, Coverage
Figure: Global Amyotrophic Lateral Sclerosis Market, Key Trends, Impact Analysis
Figure: Global Amyotrophic Lateral Sclerosis Market, Competitive Landscape, January 2022- April 2025
List of Tables
Table: Global Amyotrophic Lateral Sclerosis Market, Dynamics and Impact Analysis
Table: Global Amyotrophic Lateral Sclerosis Market, Regulatory Landscape
Table: Global Amyotrophic Lateral Sclerosis Market, (by Region), $Million, 2023-2035

Press Release